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Regulatory markerB cells are a source of inhibitory cytokines such as IL-10 and TGF-b. The ability of being B-regulatory
cells (B-regs) was shown to be driven by many stimulatory factors such as toll-like receptors, CD40-
ligand and others. However, the characterization of B-regs is still underway. B-regs express high lev-
els of CD25, CD86, IL-10 and TGF-b. In addition, we propose that semaphorin3A is a regulatory mol-
ecule and therefore can serve as one of the additional markers for B-regs. This subset of B cells was
able to suppress Th1 proliferation, thus contributing to the maintenance of self-tolerance. Finally,
the potentiation of B-reg function should become the aim of many immunomodulatory drugs, con-
tributing to a better control of autoimmune diseases.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction more open and unsolved is the issue of how to stimulate them bet-The role of B cells in the development of autoimmune diseases
has been persistently growing. Apart from being the source of
auto-antibodies, they are efﬁcient antigen-presenting-cells (APCs),
and producers of pro-inﬂammatory cytokines. It is well established
that auto-antigen-speciﬁc B cells, when present in the repertoire,
are the ﬁrst subset of APCs to capture and present self-proteins
for activating T cells [1]. On the other hand, B cells are a source
of inhibitory cytokines such as IL-10 and TGF-b. Depending on
the signals B cells receive, pro- or anti-inﬂammatory cytokines
can be produced, and the shift towards an inﬂammatory or a pro-
tective/suppressive response will be induced.
The regulatory role of B cells in autoimmunediseaseswasﬁrst re-
ported by Janeway and colleagues in a murinemodel of experimen-
tal autoimmune encephalomyletis (EAE). They showed that B cells
are not required for the induction of EAE but they may contribute
to the immune regulation resulting in complete recovery fromacute
EAE [2]. In a later study, the stimulation of arthritogenic B cells with
an agonistic anti-CD40 and collagen generated a subset of B cells
producing IL-10. The transfer of this B cell subset to syngeneic
immunized mice prevented the induction of arthritis and amelio-
rated established disease by down-regulating Th1 cytokines [3].
2. Phenotype characteristics of B-regulatory cells
The issue of how to identify B-regulatory cells (B-regs) with
membrane markers or transcription factors is yet unsolved. Eventer in order to improve their regulatory properties. In this respect,
several signals were discussed including these generated through B
cell receptor (BCR), CD40 and/or Toll-like receptors (TLRs). These
different activation signals (alone or combined) were shown by
many studies to increase regulatory functions of Bregs, but it is still
unclear which of these signals are most efﬁcient [4,5]. The question
of whether human Breg cells exist naturally or they need to be in-
duced following any immune stimulation is even less clear. CD19+-
CD25+ B cells were the ﬁrst subset of human B cells previously
suggested to have a regulatory role. They were characterized by
expressing high levels of immunoglobulins compared with CD19+-
CD25 B cells, but they lacked the ability to secrete them. They
were deﬁned to be memory B cells (being CD27+) and they ex-
pressed high levels of co-stimulatory molecules. Moreover, they
were shown to secrete high levels of inhibitory cytokine IL-10 com-
pared with CD25 B cells. Finally, they were found to present anti-
gen more efﬁciently to allogeneic CD4+ T cells in mixed
lymphocyte reaction (MLR) compared with CD25 B cells, a func-
tion that was attributed to the high expression level of CD25 [6].
In addition, CD25+ B cells were shown to display a highly activated
and mature phenotype in RA and SLE patients compared to healthy
controls. This B cell population being highly sensitive to IL-2 was
found to affect autoreactive responses and suggested to have a reg-
ulatory role in autoimmune diseases [7]. Later, CD19+CD25high B
cells were reported to be signiﬁcantly higher in patients suffering
from ANCA-related vasculitis but being in remission. However,
the level of this cell population was lower in active patients [8].
Aiming to further establish the presence of human B-regulatory
cells, CD19+CD24highCD38high B cells were assessed and deﬁned
to be regulatory being able to suppress the differentiation of Th1
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shown that their suppressive capacity was IL-10, but not TGF-b
dependent. When analyzed in SLE patients, these cells were inca-
pable of suppressing Th1 cells compared to their ability in healthy
individuals [9].
Aiming to assess the status of B-regs in allergy, a subset of IL-10
producing B cells that represents only 1–2% of splenic B cells in
naïve wild-type mice was shown to expand both in vivo and
in vitro in response to parasitic worm infection. The adoptive
transfer of these B-reg cells into allergic-sensitized mice sup-
pressed anaphylaxis and allergen-induced airway hyper-respon-
siveness. This reverse of allergic airway inﬂammation by
regulatory B cells was shown to occur in association with increased
pulmonary inﬁltration of CD4+CD25+FoxP3+regulatory T cells,
suggesting this immunoregulation to be the result of Breg–Treg
interaction [10]. In our laboratory, B cells were puriﬁed from hu-
man peripheral blood mononuclear cells (PBMCs) of healthy indi-
viduals and were stained with ﬂuorescent mAbs to CD19, CD25,
CD86 and mAbs to IL-10 and TGF-b. Gaiting on IL-10high express-
ing cells, phenotypic analyzes revealed that IL-10 high expressing
cells were also CD25high, CD86high, and TGF-bhigh. We thus, de-
ﬁned the subset of human CD19+CD25highCD86highIL-10high-
TGF-bhigh cells as B-regulatory cells [11].
Aiming to increase the understanding of B-regs and to assess
new regulatory markers we decided to analyze the relationship be-
tween semaphorin3A (Sema3A) and B-regs. Sema3A was reported
in many immune-mediated diseases to play a regulatory role. De-
creased expression of sema3A in the nasal epithelium was shown
to contribute to hypersensitivity in animal models of allergic rhini-
tis. In rescue experiments, intranasal administration of recombi-
nant sema3A to these mice alleviated sneezing and nasal rubbing
symptoms. These immuno-regulatory effects of sema3A provide a
new approach to effectively treat allergic rhinitis [12]. The involve-
ment of sema3A in psoriasis was also investigated. Here, twoFig. 1. Semaphorin3A is highly expressed on CD19/CD25 high B cells, suggesting thextracellular molecules, nerve growth factor (NGF) and sema3A
regulate nervous C-ﬁber expression. The expression level of these
two molecules in biopsy specimens from psoriatic and healthy skin
were quantiﬁed by immuno-histochemistry. Semaphorin 3A
expression was lower in psoriatic samples compared with the
healthy samples, whereas NGF was higher and found to be nega-
tively correlated with itch intensity and severity of psoriasis. This
suggests that decreased sema3A and increased NGF expression lev-
els may trigger the outgrowth of C-ﬁbers, leading to the skin
inﬂammation of psoriasis [13]. The above results encouraged us
to further investigate the protective/regulatory role of sema3A in
autoimmune diseases such as in systemic lupus erythematosus
(SLE). First, we assessed the expression of sema3A on B cells in or-
der to establish whether this expression is altered on these cells of
SLE patients. B cells were puriﬁed from healthy donors, as controls,
and from SLE patients. The puriﬁcation was done using speciﬁc
monoclonal CD22 magnetic beads (Miltenyi Biotec, Bergisch Glad-
bach, Germany) according the manufacturer instructions. We were
especially interested in how Sema3A is expressed on Breg cells,
previously reported by us to be characterized as CD19+CD25high-
CD1dhighIL-10high and TGF-bhigh [14]. When these cells were
studied in respect of Sema3A expression, we were able to show
that Sema3A is highly expressed on B cells highly expressing
CD25, suggesting this molecule to become a marker for regulatory
cells (Fig. 1). Of importance to notice that the expression of Se-
ma3A was signiﬁcantly decreased on B cells of SLE patients when
compared to that on B cells of normal individuals. We further co-
cultured normal B cells with recombinant human sema3A in order
to analyze the expression of imuuno-regulatory markers on these
cells following this incubation. The recombinant human sema 3A
was prepared in the laboratory of Prof. Gera Neufeld (Vascular Biol-
ogy and Cancer Research, Rappaport Faculty of Medicine, Technion
– Haifa) and kindly donated by him. B cells were activated with
anti-IgM and CpG-ODN, in accordance with the literature andat Sema3A could become one of the important regulatory markers on B cells.
Fig. 2. The co-culture of B cells from SLE patients with Sema3A induced a
signiﬁcant reduction in TLR-9 expression in these cells.
Fig. 3. B-regulatory cells are deﬁned to be those highly expressing CD25, CD86, IL-
10, TGF-b, and Sema3A.
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vector during 48 h. The addition of sema3A to these B lymphocytes
in culture induced a signiﬁcant increase of neuropilin-1 (NP-1)
expression (well proven to have regulatory/suppressive properties)
on these cells. This strengthens the important role of sema3A in
enhancing regulatory properties and as we show for the ﬁrst time
that sema3A increases B cell regulatory properties. We then asked
whether Toll-like receptor-9 (TLR-9) expression could possibly be
modulated in memory B cells of SLE patients following their incu-
bation with sema3A. The association between TLR-9 expression in
memory B cells and the production of inﬂammatory cytokines, e.g.
IL-6, anti-dsDNA and SLE disease severity was extensively shown
in many studies. This is why targeting TLR-9 became the subject
of many studies in the ﬁeld of SLE treatment. In one of these by
our group, IVIG was shown to attenuate TLR-9 activation in B cells
from SLE patients. In this respect we demonstrated that the addi-
tion of recombinant human sema3A, in vitro, to puriﬁed B cells
from SLE patients, signiﬁcantly reduced ODN-CpG induced TLR-9
expression in memory B cells, supporting the notion that sema3A
is important in regulating B-cell autoimmunity in SLE (Fig. 2). Fol-
lowing the above we can summarize hereby that human B-reg cells
are characterized as highly expressing CD25, CD86, IL-10, TGF-b
and Sema3A (Fig. 3).
3. The suppressive ability of human Breg cells
After determining the phenotype characteristics of Bregs, we
asked to prove that CD19+CD25high B cells (Bregs) are functionally
suppressive and able to down-regulate CD4 effector cells. The abil-
ity of Bregs to suppress proliferation of CD4+ T cells was found to
be dose dependent. Namely, the most effective suppression was
observed at a 1:1 ratio compared to 1:0.6 ratio of CD4+ T cells withBreg (Fig. 4). The results in Fig. 4A represent quantiﬁcation of CD4+
T cells divisions as measured by the dilution of CFSE ﬂuorescence
in a single experiment, where up to 4 divisions can be identiﬁed.
Analysis of the results obtained from 8 experiments indicated a re-
duced proliferation capacity of CD4+ T cells in the presence of Breg
cells (Fig. 4B). We found that in the presence of Breg cells (1:1 ra-
tio), most of the CD4+ T cells have undergone only 1–2 divisions
(G1 and G2) compared to T cells cultured alone (51.54% ± 1.74%
vs. 41.90% ± 0.71% respectively, P = 0.0002). The proportion of
CD4+ T cells that have undergone 3–4 divisions (G3–G4) was sig-
niﬁcantly reduced in the presence of Breg cells compared to T cells
cultured alone (27.14% ± 2.03% vs. 40.13% ± 2.71%, respectively,
P = 0.0004).
We next studied their ability to modify the regulatory proper-
ties of Treg cells. Breg cells were isolated using B cell isolation
kit, CD25-PE and anti-PE microbeads. From the same PBMCs, Treg
cells were puriﬁed using CD4+CD25+ T regulatory isolation kit.
Then Treg and Breg cells were co-cultured in different conditions
for 24 h at 37 C. Treg cells were co-cultured with Breg or non-Breg
cells in the presence of ODN, CD40 ligand and IL-4. As controls,
Treg cells were cultured alone at the same conditions. After 24 h,
they were stained for the detection of Foxp3 or CTLA4 (marker
for the suppressive ability of Treg cells’ function) and analyzed
by ﬂow cytometry. The results revealed that co-culture of Treg
cells with stimulated Breg cells resulted in a signiﬁcant increase
of Foxp3 levels compared with Treg cultured alone (5.93 ± 0.18
vs. 4.38 ± 0.11, P < 0.0001) (as shown in Fig. 5). However, this did
not happen when T reg cells were stimulated with non-Breg cells
(4.22 ± 0.28 vs. 4.44 ± 0.23, P = N.S.).
In summary, B-regulatory cells do exist in humans, but we still
need to better identify the stimulatory conditions that are required
in order to improve their suppressive/regulatory function. In simi-
larity with their status in animal model of many inﬂammatory dis-
eases, human B-regulatory cells are important in modifying,
autoimmunity and allergic diseases such as asthma probably by
increasing the suppressive ability of T regulatory cells.
4. Targeting Breg cells in health and in autoimmune diseases
At this stage one should ask if targeting B-reg cells could be-
come a therapeutic strategy by which autoimmunity is modiﬁed.
Anti-IL-6R (tocilizumab) was one of the ﬁrst agents which were as-
sessed in this respect. Following treatment with tocilizumab, one
might expect to achieve a reduction in both B cell activity and anti-
gen presenting properties, possibly mediated through the interrup-
tion of the autocrine IL-6/IL-6R loop on B cells. Here, we
demonstrated for the ﬁrst time that tocilizumab therapy induces
B cells to undergo phenotypic changes compatible with regulatory
function, which may partially explain the clinical response [15].
Our unique ﬁnding of a shift in B cell properties following toc-
ilizumab treatment, namely the increase in TGF-b expression and
the alteration in their activation status (CD69 expression) and
APC properties (MHC-II expression) in CD25high B cells, suggests
that the induction/expansion of B-regulatory cells may be one of
the mechanisms by which tocilizumab may possibly produce its
beneﬁcial clinical effects. The precise mechanism by which a disso-
ciation of IL-6/IL-6R complex and/or the neutralization of IL-6 sig-
naling could possibly lead to the induction or expansion of B cells
with regulatory characteristics requires better understanding. Fur-
ther studies are required to establish this important preliminary
data and to list tocilizumab among other therapies: a B cell target-
ing drug.
Trying to identify additional regulatory mechanisms, the num-
ber of IL-10-producing B cells was found to be signiﬁcantly in-
creased when B cells were co-cultured with B cell-activating
Fig. 4. B-regulatory cells are able to suppress the proliferation of activated Th cells (by increasing the proportion of generations #1, and #2) when co-cultured with B-regs in
ratio 1:0.6 but much better when co-cultured in ratio1:1.
Fig. 5. Activated B-regulatory cells increases the expression of FoxP3 in T
regulatory cells.
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(CD1d and CD86 high) possessed a regulatory function both
in vitro and in vivo, namely, inhibiting Th1 proliferation and cyto-
kine secretion [16]. This is in keeping with our previous ﬁnding ofthe change in macrophage function after rituximab treatment in
patients with RA. In association with clinical improvement, the
expression of BAFF, IL-10 and CD86 mRNA in human monocyte de-
rived macrophages was signiﬁcantly increased compared to the
values at baseline [17]. In another study we assessed the modula-
tion effects of Laquinimod on B-reg cells’ function. Laquinimod is a
novel orally administered drug under development for the treat-
ment of multiple sclerosis and under phase 3 clinical trials for sys-
temic lupus erythematosus. The exact mechanism of action of
laquinimod is under continuous investigation. Based on animal
models laquinimod has been suggested to reduce macrophage
and CD4+ T cell inﬁltration into inﬂammatory tissues, to cause a
shift in the cytokine balance from Th1 to Th2 cytokines, and to sup-
press Th17-proinﬂammatory responses. In our study, we investi-
gated the in vitro immunomodulatory effect of laquinimod on B
cell phenotype and function, on both B cells from normal individ-
uals and patients suffering from multiple sclerosis. We found that
laquinimod signiﬁcantly increased the percentage of CD25+ B cells
as well as increased the expression of IL-10 on these cells. The pro-
duction of the anti-inﬂammatory cytokine IL-10 by B cells has a
well known regulatory role. In addition, human CD25high B cells
have been shown to secrete signiﬁcantly higher levels of the im-
mune-suppressive IL-10 versus CD25low B cells, assuming that
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sults indicated that laquinimod is able to expand the subpopula-
tion of B-reg cells, as well as B-cell mediated T cell cytokine
proﬁle, suggesting this to become a future therapy in autoimmune
diseases such as in systemic lupus erythematosus [18].
These ﬁndings are relevant to our current study and the above
mentioned one, suggesting that following any immunomodula-
tory treatment such as the dissociation of IL-6/IL-6R complex
and/or the neutralization of IL-6 signaling in our case, the inter-
ference with BAFF and or the initiation of laquinimode may all
lead to the induction or expansion of B cells with regulatory
characteristics.
Finally, we are in the process of assessing whether co-culturing
B cells with Sema3A could possibly increase B-reg suppressive/reg-
ulatory functions. This is expected to be similar with the fact that
co-culturing Sema3A with T cells were able to increase their regu-
latory properties and when Sema3A was injected to CIA mice mod-
el, arthritis symptoms were ameliorated together with the
serological improvement seen in these mice [19].
In conclusion, human B-reg cells are becoming a hot issue in the
ﬁeld of autoimmunity. Further studies are needed in order to ﬁnal-
ize their precise characteristics. Finally, targeting them could be-
come a therapeutic tool for such diseases like SLE.
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